miRNA |
PubMed |
Host Gene |
Target Gene |
Location |
Fold Change |
Remark (Expression/ Alteration) |
| miR-218 | | SLIT2 | LAMB3 | NA | NA | SLIT2 encodes miR-218 and are parally expressed but is a possible target of miR-200c. Its an SNP study to determine its effect on pathway (Reduced Expression) |
| miR-218 | | SLIT2 | LAMB3 | NA | -2 | microRNA-218 (miR-218) was specifically underexpressed in HPV-positive cell lines, cervical lesions and cancer tissues containing HPV-16 DNA (Reduced Expression) |
| miR-199a | | DNM2 | NA | NA | >100 in ISCC | can be a potential therapeutic target for cervical cancer. is the most upregulated in ISCC (Over Expression) |
| miR-199a* | | DNM2 | NA | NA | >100 in ISCC | (Over Expression) |
| miR-199-s | | DNM2 | NA | NA | >100 in ISCC | (Over Expression) |
| miR-21 | | NA | PDCD4 | 17q23.2 | NA | 13-45% were found in cancer group, whereas 3-12% were identified in normal .is the only miRNA over-expressed in more than 11 types of solid tumors stomach,prostate,head and neck, esophogous, glipblastoma, neuroblastoma,cholangiocarcinoma, brest, lung,coroectal and pancreatic cancer (Over Expression) |
| miR-21 | | NA | PDCD4 | NA | NA | is the only miRNA over-expressed in more than 11 types of solid tumors stomach,prostate,head and neck, esophogous, glipblastoma, neuroblastoma,cholangiocarcinoma, brest, lung,coroectal and pancreatic cancer (Over Expression) |
| miR-34a | | NA | Notch1, Jagged1 | 1p36.23 | NA | miR-34a was expresssed in all the cell lines. Its expression levels in HeLa and C33a were very similar, whilw expression (Reduced Expression) |
| miR-200a | | NA | MYH10, ZEB1, DCP2, YWHAG, KIDINS220, ZEB2, TGFB2, RANBP5, EXOC5 | NA | NA | It simultaneously targets multiple genes (Over Expression) |
| miR-214 | | NA | MEK3, JNK1 | NA | Down regulates to 25.6-63.2% | Is a negative regulator of cell growth (Reduced Expression) |
| hsa-miR-124 | | NA | IGFBP7 | 8p23.1, 8p12.3, 20q13.33 | NA | Reduced Expression |
| miR-143 | | NA | ERK5 (MAPK7) | NA | NA | significantly reduced |
| miR-934 | | NA | NA | Xq26.3 | NA | NA |
| miR-374b | | NA | NA | Xq13.2 | NA | NA |
| miR-937 | | NA | NA | 8q24.3 | NA | NA |
| miR-939 | | NA | NA | 8q24.3 | NA | NA |
| miR-671 | | NA | NA | 7q36.1 | NA | NA |
| miR-874-5p | | NA | NA | 5q31.2 | NA | NA |
| miR-943 | | NA | NA | 4p16.3 | NA | NA |
| miR-944 | | NA | NA | 3q28 | NA | NA |
| miR-933 | | NA | NA | 2q31.1 | NA | NA |
| miR-941 | | NA | NA | 20q13.33 | NA | NA |
| miR-942 | | NA | NA | 1p13.1 | NA | NA |
| miR-935 | | NA | NA | 19q13.42 | NA | NA |
| miR-769-3p | | NA | NA | 19q13.32 | NA | NA |
| miR-940 | | NA | NA | 16p13.3 | NA | NA |
| miR-708 | | NA | NA | 11q14.1 | NA | NA |
| miR-936 | | NA | NA | 10q25.1 | NA | NA |
| miR-938 | | NA | NA | 10p11.23 | NA | NA |
| miR-203 | | NA | NA | NA | 3.704 in ISCC | (Down Regulation) |
| miR-149 | | NA | NA | NA | 2.974 in ISCC | (Down Regulation) |
| miR-127 | | NA | NA | NA | >100 in ISCC | The expression of miR-127 increase significantly in patient with lymph node metastatis (Over Expression) |
| miR-133a | | NA | NA | NA | >100 in ISCC | Over Expression |
| miR-133b | | NA | NA | Over Expression | >100 in ISCC | Over Expression |
| miR-145 | | NA | NA | NA | >100 in ISCC | Over Expression |
| miR-199b | | NA | NA | NA | >100 in ISCC | Over Expression |
| miR-214 | | NA | NA | NA | >100 in ISCC | Over Expression |
| miR-9 | | NA | NA | NA | >100 in ISCC | Over Expression |
| HMP- PREDICTED -MIR112 | | NA | NA | NA | NA | only expressed in SCC samples |
| HMP- PREDICTED -MIR128 | | NA | NA | NA | NA | only expressed in SCC samples |
| HMP- PREDICTED -MIR158 | | NA | NA | NA | NA | only expressed in SCC samples |
| HMP- PREDICTED -MIR189 | | NA | NA | NA | NA | expressed significantly higher in SCC than NT group |
| HMP- PREDICTED -MIR19 | | NA | NA | NA | NA | only expressed in NT samples |
| HMP- PREDICTED -MIR234 | | NA | NA | NA | NA | only expressed in SCC samples |
| HMP- PREDICTED -MIR235 | | NA | NA | NA | NA | only expressed in SCC samples |
| HMP- PREDICTED -MIR61 | | NA | NA | NA | NA | expressed significantly lower in SCC than NT group |
| hsa-let-7a | | NA | NA | NA | NA | expressed significantly lower in SCC than NT group |
| hsa-let-7b | | NA | NA | NA | NA | only expressed in SCC samples |
| hsa-let-7c | | NA | NA | NA | NA | expressed significantly higher in SCC than NT group |
| hsa-let-7d | | NA | NA | NA | NA | only expressed in SCC samples |
| hsa-let-7e | | NA | NA | NA | NA | only expressed in SCC samples |
| hsa-let-7f | | NA | NA | NA | NA | only expressed in SCC samples |
| hsa-miR-184 | | NA | NA | NA | NA | only expressed in NT samples |
| hsa-miR-202 | | NA | NA | NA | NA | expressed significantly higher in SCC than NT group |
| hsa-miR-21 | | NA | NA | NA | NA | only expressed in SCC samples |
| hsa-miR-214 | | NA | NA | NA | NA | only expressed in NT samples |
| hsa-miR-26a | | NA | NA | NA | NA | only expressed in SCC samples |
| hsa-miR-31 | | NA | NA | NA | NA | only expressed in SCC samples |
| hsa-miR-494 | | NA | NA | NA | NA | expressed significantly lower in SCC than NT group |
| hsa-miR-501 | | NA | NA | NA | NA | only expressed in SCC samples |
| hsa-miR-515-3p | | NA | NA | NA | NA | only expressed in SCC samples |
| mmu-miR-140 | | NA | NA | NA | NA | only expressed in NT samples |
| mmu-miR-298 | | NA | NA | NA | NA | only expressed in SCC samples |
| mmu-miR-469 | | NA | NA | NA | NA | only expressed in NT samples |
| rno-miR-352 | | NA | NA | NA | NA | only expressed in SCC samples |
| miR-9 | | NA | NA | NA | NA | Over Expression |
| miR-34a | | NA | NA | NA | NA | miR-34a was identified as a direct transcriptionaltarget of cellular transcription factor p53.This transactivation of miR-34a expression is triggered by the binding of p53 to a consensus p53 binding site identified in the miR-34a promoter region. Since HPV E6 oncoprotein destabilizes p53 during virus infection, one may assume a down-regulation of miR-34a expression in most cervical cancer tissues with oncogenic HPV infection (Reduced Expression) |
| let-7f | | NA | NA | NA | NA | Increased Expression |
| miR-100 | | NA | NA | NA | NA | Reduced Expression |
| miR-125b | | NA | NA | NA | NA | Reduced Expression |
| miR-126 | | NA | NA | NA | NA | Reduced Expression |
| miR-155 | | NA | NA | NA | NA | Increased Expression |
| miR-15a | | NA | NA | NA | NA | Increased Expression |
| miR-15b | | NA | NA | NA | NA | Increased Expression |
| miR-16 | | NA | NA | NA | NA | Increased Expression |
| miR-195 | | NA | NA | NA | NA | Reduced Expression |
| miR-199a | | NA | NA | NA | NA | Reduced Expression |
| miR-205 | | NA | NA | NA | NA | Increased expression in cancer cell line except SiHa(HPV16+), HeLa(HPV18+), and C33A(HPV-) as compared to normal cervical tissue, while these have no expression (Increased Expression) |
| miR-205 | | NA | NA | NA | NA | Increased Expression |
| miR-21 | | NA | NA | NA | NA | Over Expression |
| miR-21 | | NA | NA | NA | NA | Increased Expression |
| miR-223 | | NA | NA | NA | NA | Increased Expression |
| miR-24 | | NA | NA | NA | NA | Over Expression |
| miR-26a | | NA | NA | NA | NA | Reduced Expression |
| miR-27a | | NA | NA | NA | NA | Reduced Expression |
| miR-29a | | NA | NA | NA | NA | Reduced Expression |
| miR-424 | | NA | NA | NA | NA | Reduced Expression |
| miR-99a | | NA | NA | NA | NA | Reduced Expression |
| let-7a | | NA | NA | NA | NA | Highly Expressed in Normal |
| let-7b | | NA | NA | NA | NA | Highly Expressed in Normal |
| let-7c | | NA | NA | NA | NA | Highly Expressed in Normal |
| miR-1 | | NA | NA | NA | NA | Expressed in Normal |
| miR-125b | | NA | NA | NA | NA | Highly Expressed in Normal |
| miR-126 | | NA | NA | NA | NA | Most Highly Expressed in Normal |
| miR-133b | | NA | NA | NA | NA | Expressed in Normal |
| miR-143 | | NA | NA | NA | NA | Most Highly Expressed in Normal |
| miR-145 | | NA | NA | NA | NA | Most Highly Expressed in Normal |
| miR-182 | | NA | NA | NA | NA | Over Expressed |
| miR-183 | | NA | NA | NA | NA | Over Expressed |
| miR-195 | | NA | NA | NA | NA | Most Highly Expressed in Normal |
| miR-210 | | NA | NA | NA | NA | Over Expressed |
| miR-214 | | NA | NA | NA | NA | Expressed in normal |
| miR-26a | | NA | NA | NA | NA | Highly Expressed in Normal |
| miR-368 | | NA | NA | NA | NA | Expressed in normal |
| miR-451 | | NA | NA | NA | NA | Expressed in normal |
| miR-7029 | | NA | NA | NA | NA | Expressed in normal |
| miR-99a | | NA | NA | NA | NA | Highly Expressed in normal |
| let-7b | | NA | NA | NA | NA | Significantly Reduced |
| let-7c | | NA | NA | NA | NA | a frequency of 15-18% in normal cervical sample compare with no detection in three cell lines ,0.2% -0.4% IN TWO LINES AND 7.2% IN ONE (Significantly Reduced) |
| miR-196b | | NA | NA | NA | NA | 1-2% in normal cervical samples whereas only 0.1 in cancer cells (Significantly Reduced) |
| miR-23b | | NA | NA | NA | NA | Significanlty Reduced |
| miR-874-3p | | NA | NA | NA | NA | NA |
| ambi_miR_13143 | | NA | NA | NA | >320.8 | Over Expression |
| hsa_miR_31 | | NA | NA | NA | >13.7 | Over Expression |
| hsa_miR_106a | | NA | NA | NA | >12.2 | Over Expression |
| hsa_miR_93 | | NA | NA | NA | >8.9 | Over Expression |
| ambi_miR_9630 | | NA | NA | NA | >7.1 | Over Expression |
| hsa_miR_17_5p | | NA | NA | NA | >6.6 | Over Expression |
| hsa_miR_182 | | NA | NA | NA | >6.5 | Over Expression |
| hsa_miR_196a | | NA | NA | NA | >6.2 | Over Expression |
| miR-146a | | NA | NA | NA | >6 | Increased Expression |
| hsa_miR_30a_5p | | NA | NA | NA | >5.6 | Over Expression |
| hsa_miR_183 | | NA | NA | NA | >5.2 | Over Expression |
| hsa_miR_25 | | NA | NA | NA | NA | Over Expression |
| hsa_miR_106b | | NA | NA | NA | >4.4 | Over Expression |
| hsa_miR_224 | | NA | NA | NA | >3.6 | Over Expression |
| miR-143 | | NA | NA | NA | >2.7 | miR-143 and miR-145 are expressed from the same miRNA precursor (Reduced Expression) |
| miR-145 | | NA | NA | NA | >2.7 | Reduced Expression |
| hsa_miR_139 | | NA | NA | NA | > -3.3 | Reduced Expression |
| hsa_miR_200c | | NA | NA | NA | > -3.7 | Reduced Expression |
| hsa_miR_200a | | NA | NA | NA | > -4.6 | Reduced Expression |
| hsa_miR_329 | | NA | NA | NA | > -4.6 | Reduced Expression |
| hsa_miR_451 | | NA | NA | NA | > -5.3 | Reduced Expression |
| hsa_miR_368 | | NA | NA | NA | > -5.6 | Reduced Expression |
| hsa_miR_199a | | NA | NA | NA | > -5.7 | Reduced Expression |
| hsa_miR_214 | | NA | NA | NA | > -6.7 | Reduced Expression |
| hsa_miR_143 | | NA | NA | NA | > -6.8 | Reduced Expression |
| hsa_miR_133b | | NA | NA | NA | > -7.6 | Reduced Expression |
| hsa_miR_205 | | NA | NA | NA | > -8 | Reduced Expression |
| ambi_miR_7029 | | NA | NA | NA | > -8.4 | Reduced Expression |
| hsa_miR_145 | | NA | NA | NA | > -9.1 | Reduced Expression |
| hsa_miR_1 | | NA | NA | NA | > -9.3 | Reduced Expression |